Skip to main content
Premium Trial:

Request an Annual Quote

Stratagene Posts Lackluster Q3 Revenue Growth as Profit Falls 68 Percent

NEW YORK, Nov. 9 (GenomeWeb News) - Strategene today reported a 3-percent increase in revenues, and a 68-percent decline in profits for the three months ended Sept. 30.


Stratagene's revenues for the third quarter rose to $23.7 million from $23.1 million in the same period a year ago.


Net income fell to $700,000, or $0.03 per basic share, from $ 2.2 milllion, or $0.10 per basic share in the year-ago period.


The company also announced a one-time cash dividend of $0.25 per common share payable Jan. 6, 2006, to stockholders who have held shares in Stratagene since Dec. 16.


R&D expenditures for the quarter increased by 4 percent to $2.8 million from $2.7 million in the year ago period.


Stratagene had approximately $9 million in cash and cash investments as of Sept. 30.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.